EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

The first in‐human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT‐678 in acute coronary syndrome patients and healthy volunteers

Zhihao Liu, Shengcong Liu, Yanjun Gong, Xiying Chi, Ting Wang, Fangfang Fan, Chenxue Qu, Yaxin Lou, Long Zhang, Bin Zhang, Fan Yang, Momin Mohetaboer und 23 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17355 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Zhihao Liu und 34 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Peking University First Hospital, Beijing, China. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Platelet Aggregation Inhibitors, Clopidogrel, Cytochrome P-450 CYP2C19. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Michigan-Peking University Joint Institute for Translational and Clinical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose DT‐678 is a novel antiplatelet prodrug, capable of releasing the antiplatelet active metabolite of clopidogrel (AM) upon exposure to glutathione. In this study, we investigated factors responsible for clopidogrel high on‐treatment platelet reactivity (HTPR) in acute coronary syndrome (ACS) patients and evaluated the capacity of DT‐678 to overcome HTPR. Experimental Approach A total of 300 consecutive ACS patients naive to P2Y 12 receptor inhibitors were recruited and genotyped for CYP2C19 alleles. Blood samples were drawn before and after administration of 600‐mg clopidogrel. Platelet reactivity index (PRI) and plasma AM concentrations were determined and grouped according to their CYP2C19 genotypes. DT‐678 was applied ex vivo to whole blood samples to examine its inhibitory effects. To further examine the antiplatelet effectiveness of DT‐678 in vivo, 20 healthy human subjects were recruited in a Phase I clinical trial, and each received a single dose of either 3‐mg DT‐678 or 75‐mg clopidogrel. The pharmacokinetics and pharmacodynamics in different CYP2C19 genotype groups were compared. Key Results Statistical analyses revealed that CYP2C19 genotype, body mass index, hyperuricaemia, and baseline PRI were significantly associated with a higher risk of clopidogrel HTPR in ACS patients. The addition of DT‐678 ex vivo decreased baseline PRI regardless of CYP2C19 genotypes, overcoming clopidogrel HTPR. This observation was further confirmed in healthy volunteers receiving 3 mg of DT‐678. Conclusion and Implications These results suggest that DT‐678 effectively overcomes clopidogrel HTPR resulting from genetic and/or clinical factors in Chinese ACS patients, demonstrating its potential to improve antiplatelet therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePlatelet Aggregation InhibitorsClopidogrelCytochrome P-450 CYP2C19HumansMaleFemaleMiddle AgedAgedHealthy VolunteersAdultGenotypeBlood PlateletsDose-Response Relationship, DrugPhenylacetatesThiophenes

Stichwörter der Autor:innen

CYP2C19DT‐678acute coronary syndromehigh on‐treatment platelet reactivityplatelet reactivity index

Substanzen

Platelet Aggregation InhibitorsClopidogrelCytochrome P-450 CYP2C19CYP2C19 protein, humanmethyl 2-(2-acetoxy-6,7-dihydrothieno(3,2-c)pyridin-5(4H)-yl)-2-(2-chlorophenyl)acetatePhenylacetatesThiophenes

Autor:innen und Institutionen

  • Department of Cardiology, Peking University First Hospital, Beijing, China.
  • Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, China.
  • Department of Clinical Laboratory, Peking University First Hospital, Beijing, China.
  • Medical and Health Analytical Center, Peking University, Beijing, China.
  • Department of Phase I Clinical Trial Center, Beijing Shijitan Hospital, Capital Medical University, Beijing, China.
  • Beijing SL Pharmaceutical Co., Ltd., Beijing, China.

Förderung

  • University of Michigan-Peking University Joint Institute for Translational and Clinical Research

Zitieren

APA

Liu, Z., Liu, S., Gong, Y., Chi, X., Wang, T., Fan, F., Qu, C., Lou, Y., Zhang, L., Zhang, B., Yang, F., Mohetaboer, M., Wang, J., Qiu, L., Miao, L., Lu, Y., You, R., He, P., Li, Y., …, & Li, J. (2025). The first in‐human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT‐678 in acute coronary syndrome patients and healthy volunteers. British Journal of Pharmacology. https://doi.org/10.1111/bph.17355

Vancouver

Liu Z, Liu S, Gong Y, Chi X, Wang T, Fan F, et al. The first in‐human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT‐678 in acute coronary syndrome patients and healthy volunteers. British Journal of Pharmacology. 2025. doi:10.1111/bph.17355

BibTeX
@article{Liu2025,
  author = {Liu, Zhihao and Liu, Shengcong and Gong, Yanjun and Chi, Xiying and Wang, Ting and Fan, Fangfang and Qu, Chenxue and Lou, Yaxin and Zhang, Long and Zhang, Bin and Yang, Fan and Mohetaboer, Momin and Wang, Jie and Qiu, Lin and Miao, Linzi and Lu, Yao and You, Ran and He, Pengkang and Li, Yuxi and Yi, Tieci and Weng, Haoyu and Xia, Yulong and Wang, Chunyan and Shi, Qiuping and Wang, Zhi and Jiang, Yimeng and Li, Yinjuan and Han, Chunyu and Wang, Yu and Wang, Xinghe and Yang, Caixia and Chen, Y Eugene and Eitzman, Daniel T and Zhang, Haoming and Li, Jianping},
  title = {The first in‐human study to evaluate the antiplatelet properties of the clopidogrel conjugate DT‐678 in acute coronary syndrome patients and healthy volunteers},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17355}
}
Kostenlos starten →